Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer

Oncology

Volumn 79, Issue 1-2, 2010, Pages 98-104

  Sánchez Muñoz, Alfonso ^a   Mendiola, César ^b   Pérez Ruiz, Elisabeth ^a   Rodríguez Sánchez, César A ^c   Jurado, José Miguel ^a   Alonso Carrión, Lorenzo ^a   Ghanem, Ismael ^b   De Velasco, Guillermo ^b   Quero Blanco, Cristina ^a   Alba, Emilio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Bevacizumab; Cyclophosphamide; Recurrent ovarian cancer

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTERIAL ISCHEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; HEMATURIA; HUMAN; HYPERTENSION; INTESTINE FISTULA; ISCHEMIA; LEG THROMBOSIS; LOW DRUG DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PROTEINURIA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADMINISTRATION, ORAL; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ENDOMETRIOID; CYCLOPHOSPHAMIDE; CYSTADENOCARCINOMA, SEROUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; TREATMENT OUTCOME;

EID: 78149433404     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320602     Document Type: Article

References (22)

1. Jemal A, et al: Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Harries M, Gore M: Part I: chemotherapy for epithelial ovarian cancer treatment as first diagnosis. Lancet Oncol 2002; 3: 529-536. 3
3. Markman M: Pharmaceutical management of ovarian cancer: current status. Drugs 2008; 68: 771-789.
4. Ellis L, Fidler I: Angiogenesis and metastasis. Eur J Cancer 1996; 32A:2451-2460.
5. Bamberger ES, Perret CW: Angiogenesis in epithelial ovarian cancer. Mol Pathol 2002; 55: 348-359.
6. Cohn DE, Valmadre S, Resnick KE, et al: Bevacizumab and weekly taxane chemotherapy demonstrate activity in refractory ovarian cancer. Gynecol Oncol 2006; 102: 134-139.
7. Monk BJ, Han E, Josephs-Cowan CA, et al: Salvage bevacizumab (rhuMAB VEGF)- based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006; 102: 140-144.
8. Wright JD, Hagemann A, Rader JS, et al: Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006; 107: 83-89.
9. Richardson DL, Backes FJ, Seamon LG, et al: Combination gemcitabine, platinum and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol 2008; 111: 461-466.
10. Burger RA, Sill MW, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 5165-5171.
11. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-5186.
12. Garcia AA, Hirte H, Fleming G, et al: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 2008; 26: 76-82.
13. Nimeiri HS, Oza AM, Morgan RJ, et al: Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago PMH, and California Phase II Consortia. Gynecol Oncol 2008; 110: 49-55.
14. McGonigle KF, Muntz HG, Vuky JL, et al: Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (abstract). J Clin Oncol 2008; 26(suppl):5551.
15. Hurt JD, Richardson DL, Seamon LG, et al: Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2009; 115: 396-400.
16. Kikuchi Y, et al: Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer (abstract). J Clin Oncol 2009; 27(suppl):5547.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors - European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
18. Rustin GJ: Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21(suppl 10):187s-193s.
19. Sánchez-Muñoz A, Pérez-Ruíz E, Alba E, et al: Second complete remission induced by ciclophosphamide plus bevacizumab in two patients with heavily pretreated ovarian cancer. Clin Transl Oncol 2009; 11: 329-331.
20. Han ES, Monk BJ: What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007; 105: 3-6.
21. Simpkins F, Belinsonq JL, Rose PG: Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 2007; 107: 118-123.
22. Burger RA, Brady MF, Bookman MA, et al: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. Program and Abstracts 2010 Annu Meet Am Soc Clin Oncol, Chicago, 2010, abstract LBA1.